New developments in the pharmacological treatment of macular oedema due to retinal vein occlusion;Neue Entwicklungen in der pharmakologischen Therapie des Makulaödems bei retinalen Venenverschlüssen

Klinische Monatsblatter fur Augenheilkunde

Volumn 228, Issue 9, 2011, Pages 793-800

  Lang, G E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

branch retinal vein occlusion; central retinal vein occlusion; Lucentis, dexamethasone, Ozurdex; macular oedema; ranibizumab; retinal vein occlusion

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB;

ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LOW LEVEL LASER THERAPY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD-RETINAL BARRIER; CYTOKINES; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; INTRAOCULAR PRESSURE; MACULAR EDEMA; RETINAL VEIN OCCLUSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052568754     PISSN: 00232165     EISSN: 14393999     Source Type: Journal    
DOI: 10.1055/s-0031-1281712     Document Type: Article

References (11)

1. Lang G E., Lang S J. Diagnostik und Therapie retinaler Venenverschlüsse. Klin Monatsbl Augenheilkd 2010 227 R141-R155
2. Lang G E. Zentralvenenverschlüsse. Klin Monatsbl Augenheilkd 2007 224 R95-R109
3. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss. Klin Monatsbl Augenheilkd 2010 227 542-556
4. Feltgen N, Pielen A, Hansen L et al. Intravitreale Medikamenteneingabe bei retinalem Venenverschluss pathophysiologische Mechanismen und angewandte Substanzen. Klin Monatsbl Augenheilkd 2010 227 681-693
5. Haller J A., Bandello F, Belfort R et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010 117 1134-1147
6. Deissler H, Deissler H, Lang S et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008 92 839-843 (Pubitemid 351839580)
7. Haller J A., Bandello F, Belfort Jr R et al. Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion Twelve-Month Study Results. Ophthalmology 15 Jul 2011 [Epub ahead of print]
8. Brown D, Campochiaro P A., Singh R P. et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010 117 1124-1133
9. Campochiaro P A., Brown D M., Awh C C. et al. Sustained benefits from Ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 27 Jun 2011 [Epub ahead of print]
10. Campochiaro P A., Heier J S., Feiner L et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010 117 1102-1112
11. Brown D M., Campochiaro P A., Bhisitkul R B. et al. Sustained benefits from Ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011 118 1594-1602